TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Cystine Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Cured Patients
Endpoint domain: Mortality/survival
Primary endpoint: Correlation between anterior temporal and subgenual frontal fMRI signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive impairment assessed with the Mini-Mental State Examination (MMSE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive impairment assessed with the Clock Drawing Test (CDT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive impairment assessed with the Digit Symbol test (DST)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive impairment assessed with the Wechsler Memory Scale (WMS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive impairment assessed with the Aphasia Battery of Chinese (ABC)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mood assessed with the patient health questionnaire -9 (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Inter-rectus distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Survivors With no Severe IVH or PVL
Endpoint domain: Mortality/survival
Primary endpoint: Composite Outcome of Necrotizing Enterocolitis, Intraventricular Hemorrhage, Bronchopulmonary Dysplasia and Retinopathy of Prematurity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of HF related events
Endpoint domain: Adverse events/effects
Primary endpoint: Negative biopsy cores at the site of focal ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in lipid/lipoprotein profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Myocardial FA extraction fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absolute change in flap vascular resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Early Identification Rate (EIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Respiratory Assessment Measure (PRAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean per-member-per-month total health care costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of acute GvHD
Endpoint domain: Adverse events/effects
Primary endpoint: CEUS true positive diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CEUS false positive diagnosis
Endpoint domain: Adverse events/effects
Primary endpoint: CEUS true negative diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CEUS false negative diagnosis
Endpoint domain: Adverse events/effects
Primary endpoint: 3-year Disease-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Respiratory mucus transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Stone-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Characterization of amyloid protein deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in airborne nicotine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Improvement of Influenza Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acupoint temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants using a safe drug disposal method
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area Under Curve From 0 to 1 Hour at Steady State (AUC0-1,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement of truth and reported dietary intake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Functional Outcome (modified Rankin Scale 0-6)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Functional Independence (modified Rankin Scale 0-2)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Favorable Outcome (modified Rankin Scale 0-1)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: proportion of patients with genotype IL-28B C/C versus IL-28B non C/C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants With at Least One Treatment Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Total Number of Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Level of Interleukin 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of TNF-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma Concentration of Raltegravir at 12 Hours (C 12 Hrs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC 0-12 Hrs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (C Max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ellipsoid zone (area of IS/OS loss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients no longer presenting S9.6:D5H6 RNA:DNA duplex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological complete response (PCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of brain activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to withdrawal due to insufficient analgesic efficacy
Endpoint domain: Adverse events/effects
Primary endpoint: transparency and quality of the transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of patients reaching SBP goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of subjects free from device/procedure related Major Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Subclinical organ damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with laboratory-confirmed COVID-19
Endpoint domain: Adverse events/effects
Primary endpoint: number of cancer detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Laryngeal dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Memory performances
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Plasma concentration level (Cmax and Co) of clonidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: (11)C-FMZ binding potential (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Physiological benefits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prenatal maternal attachment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Distress in pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cognitive function - Attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive function - Executive functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Scoring of the WELCH
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dry Blood Spot (DBS) MK-1602 Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Reporting Pain Freedom (PF)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With Pain Relief (PR)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent time within target glucose range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients who achieve target goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite safety endpoint of Target Lesion Failure (TLF) at 30 days post-procedure
Endpoint domain: Adverse events/effects
Primary endpoint: In-stent late loss at 6 month post-procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma levels of 15-epi-lipoxin A4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC(0-inf)) of Atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence/Absence of Abnormal 18F- Fluorothymidine (FLT) Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Positive/Negative Biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in HAM-D17 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ingested caloric intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of successful venous access on the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of adverse events associated with either the treatment or the venous access site
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in circulating tumor nucleic acids (CK7, ELF3, EGFR and EphB4 mRNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage Change in Inflammatory Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Self-assessed Likert Scale Relating to Confidence in Breaking Bad News
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Simulated Patient Encounter Marking Scores Related to Breaking Bad News
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of dilation procedures within 6 months of follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total number of dilation procedures during first dilation session to 16-18mm
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CMV-specific, CD8+ T-cell immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complete histologic eradication of heterotopic gastric mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of subjects with immediate reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with solicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with any unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: rate of post-operative surgical complications
Endpoint domain: Adverse events/effects
Primary endpoint: PCR positivity correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-free Survival (DFS) at Month 18
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy of Rosiglitazone Maleate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence of root canal curvatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Axillary Admission Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Axillary Temperature at 4 Hours of Infant Life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose determination of GCSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral nucleic acid test negative conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Need for intubation
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of death during hospital stay
Endpoint domain: Mortality/survival
Primary endpoint: Presence of diabetic polyneuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of painful diabetic polyneuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response rate (complete response, partial response, and minimal response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Total Phase II Participants With Chemotherapy Pre-Treated Triple Negative Metastatic Breast Cancer Who Are Progression Free at 3 Months
Endpoint domain: Mortality/survival
Primary endpoint: Change in Manic Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in limb fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage change in low density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patients experience of specialized eating disorder care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tmax = Time of maximum concentration of PF-05089771 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Oxysterols
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of arginine-NO metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peri and intra prosthetic leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: In situ effects of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: infiltration of CD8+ tumor infiltrating lymphocytes (TILs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum erythropoietin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lesion size measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: number of biological samples collected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Serum 1,25(OH)2D Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Serum PTH Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: End of Treatment Abstinence Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: End of Follow-up Abstinence Rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adequate Alignment of the forearm fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of subjects with standard safety laboratory test results of potential clinical significance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cohort of patients with CKD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aspiration reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specimen hemolysis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global peak systolic longitudinal strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: brain response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Any competitive employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: diagnostic performance for staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: toxicity and safety
Endpoint domain: Adverse events/effects
Primary endpoint: Short-term Safety Concerns for Ablative Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of Treatment by Women
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Renal Function by Glomerular Filtration Rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Metabolic normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gastro-intestinal side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma total amino acid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disability measured by NODI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-inf)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beta cell secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulin sensitivity/glucose effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Gastrointestinal Symptom VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Concentration of aerosol generated during the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking Urges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nicotine Withdrawal - Negative Affect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose Limiting Toxicity (DTL)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Clostridium difficile bacterial loads
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in IBDQ-B score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of detection of bladder malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Length of Postoperative Hospital Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: colour vision reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of right-to-left shunt on TCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of cerebrovascular reactivity on TCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: iron-deficiency anemia morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Alleviation of bone pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Response to Treatment Based on Hemoglobin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Uterine contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Hormone measurements (TSH, PTH, Total T4, free T4, total T3, free T3, prolactin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Anti-platelet autoantibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum tolerated dose of TAS-114
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of TcB in predicting Serum Bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood Lead Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Any Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Prevention of pulmonary mucus obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean continuous glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Completion of modified Yoga program
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Plasma HIV-1 RNA >=50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Measured medical observations and clinical investigations outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type of physiotherapy treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of the first physiotherapy treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Aggregate Rate of Airway and Respiratory Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: The level of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Severity
Endpoint domain: Adverse events/effects